Plain-English translation of NCT07617688 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-phase trial testing [18F]MODAG-009, a new radioactive tracer designed to help doctors see what's happening inside the body during imaging scans. Researchers want to understand how this medication moves through your body, where it goes, and how much radiation you would receive. This information will help them determine if this new imaging tool is safe and useful for future patients.
Before this medication can be used to help diagnose patients, researchers need to understand how it behaves in the human body and ensure it delivers the right amount of radiation for a diagnostic scan.
You likely qualify if…
You likely don't qualify if…
You would come to the study center on one day to receive a single injection of the new tracer into your vein, followed by imaging scans that take place over about 6 hours. During this time, you'll have whole-body imaging sessions, and researchers will collect blood and urine samples to track how your body processes the medication. About a week after your visit, you'll return for a follow-up check to make sure everything is fine, and you'll have additional safety tests like heart rhythm monitoring and lab work.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States